NCT01374776View on ClinicalTrials.gov

Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance in Premenopausal Women

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

December 31, 2014

Conditions
Non Anemic Patients With Iron Deficiency (Low Ferritin Value)
Interventions
DRUG

intravenous iron carboxymaltose

The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.

Trial Locations (1)

8091

University Hospital Zurich, Clinic and Policlinic of Internal Medicine, Zurich

All Listed Sponsors
lead

University of Zurich

OTHER

NCT01374776 - Effect Of Intravenous Iron Versus Placebo On Muscle Oxidative Capacity And Physical Performance in Premenopausal Women | Biotech Hunter | Biotech Hunter